All questionsSpecific populations: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer1 question · 1 sourceSpecific populationsCan KEYTRUDA be used during pregnancy or breastfeeding?“Based on their mechanism of action, KEYTRUDA and KEYTRUDA QLEX can each cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA or KEYTRUDA QLEX and advise them to use effective contraception during treatment and for 4 months after the last dose.” (opens the source at this quote in a new tab)CopyFlag“Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.” (opens the source at this quote in a new tab)CopyFlag